tiprankstipranks
pc:kaile

Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing advanced therapies for obesity treatment. The company is advancing a diverse portfolio of injectable and oral therapies, including its lead candidate, KAI-9531, an injectable dual GLP-1/GIP receptor agonist. Kailera aims to deliver next-generation weight management solutions that empower individuals to improve their health and quality of life. Based in Waltham, MA, and San Diego, CA, Kailera is focused on addressing the global obesity challenge through innovative therapeutic approaches.

Leadership & Board

Current Number of Employees150
Current LinkedIn Followers14,405

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$600M
Total Amount Raised$600M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$600M
Latest Funding Amount$600M
Latest Funding RoundSeries B
Latest Funding RoundSeries B
Post-Money Valuation
Post-Money Valuation

Employee Trend

Kailera Therapeutics had 150 employees as of April 6, 2026. The number of employees increased by 2 (1.35%) week-over-week.
150Latest Employee Count
2(1.35%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Kailera Therapeutics had 14,405 followers as of April 6, 2026. The number of followers increased by 137 (0.96%) week-over-week.
14,405Latest Followers Count
137(0.96%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 14, 2025
Series B
$600.00M

Investors

Related News and Analysis